LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $105.80.

Several research firms have recently issued reports on LMAT. Citizens Jmp raised their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Finally, Barrington Research raised their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th.

Insider Activity

In other news, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company’s stock, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 55,930 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $107.81, for a total value of $6,029,813.30. Following the completion of the sale, the chief executive officer directly owned 1,476,500 shares of the company’s stock, valued at $159,181,465. The trade was a 3.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 215,438 shares of company stock valued at $23,062,911 in the last ninety days. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the business. Vest Financial LLC lifted its stake in shares of LeMaitre Vascular by 60.0% during the 3rd quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock worth $4,925,000 after acquiring an additional 21,102 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $1,101,000. Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock worth $59,392,000 after acquiring an additional 40,065 shares during the last quarter. Public Sector Pension Investment Board lifted its stake in shares of LeMaitre Vascular by 15.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 81,211 shares of the medical instruments supplier’s stock worth $7,107,000 after acquiring an additional 11,092 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $6,056,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $112.80 on Thursday. The stock has a 50 day moving average of $106.17 and a 200 day moving average of $92.90. LeMaitre Vascular has a 12 month low of $78.01 and a 12 month high of $118.01. The firm has a market cap of $2.58 billion, a PE ratio of 44.94, a PEG ratio of 3.22 and a beta of 0.67. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The company had revenue of $64.45 million during the quarter, compared to analyst estimates of $62.98 million. During the same period in the prior year, the company earned $0.49 earnings per share. The firm’s revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, research analysts expect that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Thursday, March 12th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio is 39.84%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.